Brief: Transgene To Present Updated Positive Preliminary Data From Phase I Clinical Trials With TG4050 (Myvac Platform) At ASCO 2022

Transgene SA

27/05/2022 07:08

May 27 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE TO PRESENT UPDATED POSITIVE PRELIMINARY DATA
FROM THE
PHASE I CLINICAL TRIALS WITH TG4050 (MYVAC® PLATFORM) AT ASCO
2022
    * ABSTRACT REPORTS POSITIVE IMMUNOGENICITY AND CLINICAL DATA
GENERATED FROM TWO ONGOING PHASE I TRIALS IN PATIENTS WITH
OVARIAN CANCER AND HPV-NEGATIVE HEAD AND NECK CANCER
(NCT03839524 AND NCT04183166)

Source text for Eikon:  ID:nBw8K7Vg9a 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))